Sign In
Buy EXAS
$104.91
+0 (+0%)
At Close: Jun 03, 2026
NYSE Exec: There's 1 Stock In Cathie Wood's Fund That's Ready To Rise (It's Not Tesla)
04:33pm, Thursday, 05'th Jan 2023
As of Thursday, the ARK Innovation ETF ARKK held 31 stocks. But there's only one name in the entire basket that appeals to Jay Woods, chief market strategist at Drive Wealth and NYSE executive floor
War, Inflation, Fed Hawkishness, Elon Musk's Twitter Buy: How These Factors Weighed On Cathie Wood's Top Holdings In 2022
07:51am, Monday, 02'nd Jan 2023 Benzinga
In 2022, financial markets witnessed one of the worst routs in history, dragged by the war in Ukraine, rising inflation and subsequent hawkish policies deployed by central banks.
What Happened: Pessim
3 Reasons to Retain Surmodics (SRDX) Stock in Your Portfolio
02:31pm, Friday, 30'th Dec 2022 Zacks Investment Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.
3 Hot Mid-Caps During a Cold December
07:34pm, Thursday, 29'th Dec 2022 Zacks Investment Research
Despite the market's cold performance in December, these three stocks have remained hot, snapping the bearish trend. Their earnings outlooks suggest even more upside in 2023.
3 Hot Mid-Caps During a Cold December
03:48pm, Thursday, 29'th Dec 2022
Despite the market's cold performance in December, these three stocks have remained hot, snapping the bearish trend. Their earnings outlooks suggest even more upside in 2023.
3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio
03:20pm, Thursday, 29'th Dec 2022 Zacks Investment Research
Investors continue to be optimistic about Nevro (NVRO), owing to its R&D edge.
3 Reasons to Retain Glaukos (GKOS) Stock in Your Portfolio
04:06pm, Wednesday, 28'th Dec 2022 Zacks Investment Research
Investors continue to be optimistic about Glaukos (GKOS) on the back of continued strength in its flagship iStent.
3 Reasons to Retain OPKO Health (OPK) Stock in Your Portfolio
03:06pm, Wednesday, 28'th Dec 2022 Zacks Investment Research
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in RAYALDEE.
Cathie Wood Says Risk-Off Environment Pushed Investors Back Toward Benchmarks: 'While Innovation Solves Problems...'
02:09pm, Wednesday, 28'th Dec 2022 Benzinga
Cathie Wood has acknowledged in her year-end newsletter that a risk-off market environment has pushed investors back toward benchmarks during the last two years, disadvantaging strategies that focus o
3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio
03:49pm, Tuesday, 27'th Dec 2022 Zacks Investment Research
Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.
McKesson (MCK) Announces Availability of FDA-Accepted Drug
06:15pm, Friday, 23'rd Dec 2022 Zacks Investment Research
The availability of FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for PEComa.
3 Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio
12:44pm, Thursday, 22'nd Dec 2022 Zacks Investment Research
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Here's Why You Should Retain NextGen (NXGN) Stock for Now
03:15pm, Wednesday, 21'st Dec 2022 Zacks Investment Research
NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.
McKesson (MCK) Announces Availability of FDA-Approved Drug
02:04pm, Wednesday, 21'st Dec 2022 Zacks Investment Research
The availability of FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for AML.
Are Growth Investors Finally Cutting Ties With Cathie Wood? Ark Innovation Flows Vanish As Flagship Fund Hits 5-Year Low
06:32pm, Tuesday, 20'th Dec 2022 Benzinga
ARK Innovation ETF (ARCA: ARKK) hit new five-year lows on Tuesday, led by declines in the top holdings of Ark's flagship fund. As ARKK continued its two-year slide, it appeared some investors h
